Global Cardiac Marker Testing Market Report (2022 to 2027)

Global Cardiac Marker Testing Market

Dublin, Oct. 31, 2022 (GLOBE NEWSWIRE) -- The "Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hs-CRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The global cardiac marker testing market is projected to reach USD 7.7 Billion by 2027 from USD 5.0 Billion in 2022, at a CAGR of 8.7% during the forecast period.

Troponin I and T estimated held the largest share of cardiac marker testing market in 2021, by Biomarker Type

Based on biomarker type, the cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Natriuretic Peptide (BNP and Nt-proBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment accounted for the largest share of 51.1 % of the cardiac marker testing market in 2021.

Factors such as high sensitivity and specificity, long elevation time (rises over 4-8 hours, peaks at 10-24 hours, and declines over ten days), and rapid prediction of outcomes are driving the growth of this segment. In addition, lab technicians are more familiar with the use of these markers as compared to other biomarkers

Laboratory testing facilities segment accounted for the largest share of the cardiac marker testing market in 2021, by End user

Based on end users, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2021, the laboratory testing facilities segment accounted for the largest share of 61.4% of the global cardiac marker testing market. Factors such as high testing throughput, better sensitivity & diagnostic accuracy compared to POC testing, and high preference for laboratory testing over POCT testing are driving the growth of this segment.

The Asia Pacific market to grow at the highest CAGR during the forecast period

The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period.

The Asia Pacific market is driven due rising growing investments by government agencies in emerging countries of Asia Pacific for the improvement of healthcare infrastructure, growing number of independent clinical laboratories, presence of large patient population, and strategies adopted by players to increase their cardiac testing product reach in Asia Pacific.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Cardiac Marker Testing Market Overview4.2 Cardiac Marker Testing Market Share, by Product, 2022 vs. 20274.3 Europe: Cardiac Marker Testing Market, by End-user and Region4.4 Cardiac Marker Testing Market: Geographical Snapshot

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Rising Incidence of Cardiovascular Diseases5.2.1.2 Increasing Geriatric Population and Subsequent Rise in Heart Conditions Worldwide5.2.1.3 Growing Research & Funding Initiatives from Public & Private Organizations5.2.1.4 Rising Clinical Studies for Identification of Novel Cardiac Biomarkers5.2.2 Restraints5.2.2.1 Technical Issues Related to Sample Collection & Storage5.2.2.2 Unfavorable Regulatory Processes and Limited Reimbursement Structure5.2.3 Opportunities5.2.3.1 Point-Of-Care Testing with Cardiac Biomarkers5.2.3.2 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases5.2.3.3 Emerging Markets Offer High-Growth Opportunities5.2.4 Challenges5.2.4.1 Challenges Associated with Biomarker Assay Validation5.3 Regulatory Scenario5.4 Reimbursement Scenario5.5 Value Chain Analysis5.6 Supply Chain Analysis5.7 Ecosystem Analysis: Parent Market (In Vitro Diagnostics)5.8 Pricing Analysis5.8.1 Average Selling Price of Cardiac Market Test Kits by Key Players5.9 Porter's Five Forces Analysis5.10 Patent Analysis5.11 Key Conferences & Events (2022-2024)5.12 Case Study5.12.1 Development of High-Sensitivity Troponin I5.13 Trends/Disruptions Impacting Customers' Businesses5.14 Key Stakeholders & Buying Criteria5.14.1 Key Stakeholders5.15 Key Buying Criteria by End-users

6 Cardiac Marker Testing Market, by Product6.1 Introduction6.2 Reagents & Kits6.2.1 Rising Volume of Diagnostic Tests to Drive Demand6.3 Instruments6.3.1 Chemiluminescence6.3.1.1 Most Preferred Method for Quantification of Cardiac Biomarkers to Drive Segment Growth6.3.2 Immunofluorescence6.3.2.1 Demand for Stable and Safer Reagents to Support Market Growth6.3.3 Elisa6.3.3.1 Long Shelf Life and Ease of Use to Propel Segment Growth6.3.4 Immunochromatography6.3.4.1 Increasing Use in Point-Of-Care Settings to Drive Adoption of this Technique

7 Cardiac Marker Testing Market, by Biomarker Type7.1 Introduction7.2 Troponin I and T7.2.1 High Sensitivity and Specificity in Detection of CVD to Drive Market7.3 Creatine Kinase-Mb (Ck-Mb)7.3.1 Diagnosis of Acute Myocardial Injury Using Ck-Mb to Drive Market7.4 Natriuretic Peptide (BNP and Nt-Probnp)7.4.1 Use of Bnp with Other Cardiac Markers to Enhance Utilization7.5 Myoglobin7.5.1 Rapid Increase and Normalization Associated with Myoglobin to Drive Market7.6 High-Sensitivity C-Reactive Protein (Hscrp)7.6.1 Ability of Hscrp Tests to Accurately Measure Low Levels of Crp to Support Market Growth7.7 Other Cardiac Biomarkers

8 Cardiac Marker Testing Market, by Disease8.1 Introduction8.2 Myocardial Infarction8.2.1 Availability of High-Sensitivity Biomarkers for Detection of Mi to Drive Market8.3 Congestive Heart Failure8.3.1 Increasing Use of Multi-Marker Testing to Support Market Growth8.4 Acute Coronary Syndrome8.4.1 Increasing Incidence of Risk Factors Associated with Acs to Drive Adoption of Cardiac Markers8.5 Atherosclerosis8.5.1 High Prevalence of Atherosclerosis to Drive Uptake of Cardiac Markers8.6 Ischemia8.6.1 Multiple Complications Caused by Ischemia to Drive Adoption of Diagnostic Tests

9 Cardiac Marker Testing Market, by End-user9.1 Introduction9.2 Laboratory Testing Facilities9.2.1 Hospital Laboratories9.2.1.1 Emergency Patient Care and Early Diagnosis Associated with In-House Labs to Drive Market9.2.2 Reference Laboratories9.2.2.1 Affordable and Time-Efficient Services Associated with Reference Laboratories to Support Market Growth9.2.3 Contract Testing Laboratories9.2.3.1 Ability to Perform Multiple Tests and Cover Wider Matrices to Support Market Growth9.3 Academic Institutes9.3.1 Continuous Research & Development of Novel Biomarkers to Drive Market9.4 Point-Of-Care Testing Facilities9.4.1 Early Detection and Lower Turnaround Time to Drive Market

10 Cardiac Marker Testing Market, by Region

11 Competitive Landscape11.1 Overview11.2 Strategies Adopted by Key Players/Right to Win11.3 Revenue Analysis11.4 Cardiac Marker Testing Market: Market Share Analysis, by Key Player (2021)11.5 Company Evaluation Quadrant for Major Players (As of 2021)11.5.1 Stars11.5.2 Emerging Leaders11.5.3 Pervasive Players11.5.4 Participants11.6 Company Evaluation Quadrant (SMEs/Startups)11.6.1 Progressive Companies11.6.2 Responsive Companies11.6.3 Dynamic Companies11.6.4 Starting Blocks11.7 Competitive Benchmarking11.8 Competitive Scenario (2019-2022)11.8.1 Product Launches & Approvals11.8.2 Deals11.8.3 Other Developments

12 Company Profiles12.1 Key Players12.1.1 F. Hoffmann-La Roche AG12.1.2 Abbott Laboratories12.1.3 Siemens Healthineers AG12.1.4 Danaher Corporation12.1.5 Biomerieux SA12.1.6 Becton, Dickinson and Company (Bd)12.1.7 Bio-Rad Laboratories, Inc.12.1.8 Thermo Fisher Scientific Inc.12.1.9 Diasorin12.1.10 Perkinelmer, Inc.12.1.11 Tosoh Corporation12.1.12 Lsi Medience Corporation (Phc Holdings Corporation)12.1.13 Quidel Corporation12.1.14 Randox Laboratories12.1.15 Guangzhou Wondfo Biotech Co. Ltd.12.1.16 Boditech Med Inc.12.1.17 Tulip (P) Diagnostics Ltd.12.1.18 Btnx Inc.12.1.19 Response Biomedical12.1.20 Alfa Scientific Designs, Inc.12.2 Other Players12.2.1 Ctk Biotech, Inc.12.2.2 Creative Diagnostics12.2.3 Lifesign LLC.12.2.4 Cardiogenics Holdings Inc.12.2.5 Atlas Medical GmbH

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/r1jkor

Attachment

Global Cardiac Marker Testing Market